African malaria vaccine researcher discusses late-stage clinical trial

With the Day of the African Child drawing attention to the lives of children across the continent, a leading African malaria vaccine researcher discusses progress in the clinical testing of the PATH Malaria Vaccine Initiative's leading vaccine candidate—GlaxoSmithKline Biologicals’ RTS,S. Read more »

KEMRI/WRAIR co-principal investigator Dr. Walter Otieno examines trial participant

Partnering with us

We are pursuing a range of vaccine development approaches with an expanding circle of industry, academic, and government partners.

Our portfolio

MVI portfolio graphicWe maintain a diverse portfolio of projects, including preclinical feasibility studies, translational projects, and one advanced clinical project.

View the portfolio »

What we do and how we do it

We provide funding and technical support to partners worldwide to accelerate the development of malaria vaccines. We also work to ensure that malaria vaccines will reach those who need them.

Read more »

Photo: Darby Communications/John-Michael Maas

News and announcements

 

MVI announces collaboration to develop vaccine approach against Plasmodium vivax

New approach aims to target second most serious malaria-causing parasite.

 

MVI receives high marks in key areas of its work

A recent evaluation of the operations and research portfolio of the PATH Malaria Vaccine Initiative assesses as "outstanding" MVI's engagement with industry and its use of milestones to measure progress.

 

What's on the horizon for malaria vaccine development?

Ashley Birkett, Director of Pre- and Early-Clinical Research and Development, talks about our strategy to control and eventually eliminate malaria

 

More news »